Changing horses

FRAMINGHAM (01/15/2004) - De Novo Pharmaceuticals Ltd. has abandoned in silico drug design to focus on commercializing proprietary discovery platforms. The company intends to collaborate with pharmaceutical and biotech firms that want to use De Novo platforms such as the chemical structure generator SkelGen. Closing its discovery labs resulted in job losses for half of the company's 48 employees.

Join the newsletter!


Sign up to gain exclusive access to email subscriptions, event invitations, competitions, giveaways, and much more.

Membership is free, and your security and privacy remain protected. View our privacy policy before signing up.

Error: Please check your email address.
Show Comments